Search results - Portal of Medical Data Models (MDM-Portal)

Filter search results
Select data models

Selected data models

You must log in to select data models for download or further analysis.

5 Search results.

Neurological Examination Week 38 Mepolizumab HES NCT00086658 - Neurological Examination Week 38

- 7/15/17 - 1 form, 1 itemgroup, 18 items, 1 language

Itemgroup: Neurological Examination

Study part: Neurological Examination Week 38/ Early Withdrawal visit.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Neurological Examination Week 16 Mepolizumab HES NCT00086658 - Neurological Examination Week 16

- 7/12/17 - 1 form, 1 itemgroup, 18 items, 1 language

Itemgroup: Neurological Examination

Study part: Neurological Examination Week 16. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Neurological Examination Week 8 Mepolizumab HES NCT00086658 - Neurological Examination Week 8

- 7/9/17 - 1 form, 1 itemgroup, 18 items, 1 language

Itemgroup: Neurological Examination

Study part: Neurological Examination Week 8. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Neurological Examination Week 4 Mepolizumab HES NCT00086658 - Neurological Examination Week 4

- 6/11/17 - 1 form, 1 itemgroup, 18 items, 1 language

Itemgroup: Neurological Examination

Study part: Neurological Examination Week 4. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Neurological Examination Day 1 Pre-Infusion Mepolizumab HES NCT00086658 - Neurological Examination Day 1 Pre-Infusion

- 6/11/17 - 1 form, 1 itemgroup, 18 items, 1 language

Itemgroup: Neurological Examination

Study part: Neurological Examination Day 1 Pre-Infusion.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Please use this form for feedback, questions and suggestions for improvements.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.